PubMed
Intranasal oxytocin in humans: a review of neurobiological and behavioral effects
Striepens N, Kendrick KM, Maier W, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 49% · Mixed 42% · Unfavorable overall 9%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 200–400 mcg · Most common: 400–600 mcg
Reports span 50–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 41% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 21 days · Based on 362 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 45% · Mixed 38% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.05–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 29 days · Based on 427 repeat reporters
Published sources linked on the Oxytocin and PT-141 wiki pages.
PubMed
Striepens N, Kendrick KM, Maier W, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013
FDA Drug Label
Par Pharmaceutical. FDA Drug Label. 2014
PubMed
Heinrichs M, Baumgartner T, Kirschbaum C, et al. Biological psychiatry. 2003
PubMed
Yin H, Jiang M, Han T, et al. Peptides. 2024
FDA Drug Label
AMAG Pharmaceuticals. FDA Drug Label. 2019
PubMed
Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Pettigrew JA, Novick AM. Journal of midwifery & women's health. 2021
PubMed
Burton CS, Mishra K. Current opinion in obstetrics & gynecology. 2022